Thursday, January 23, 2020

The FDA last week approved Novo Nordisk's Ozempic to...

..."reduce the risk of major adverse cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease," an expansion of the drug's current type 2 diabetes indication. For the treatment of type 2 diabetes, Ozempic currently holds preferred formulary status for 44% of all covered lives.

SOURCE: MMIT Analytics, as of 1/22/20

No comments:

Post a Comment